Back to top
more

Cyclerion Therapeutics (CYCN)

(Delayed Data from NSDQ)

$2.93 USD

2.93
276

-0.11 (-3.62%)

Updated Apr 26, 2024 02:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates

Cyclerion Therapeutics, Inc. (CYCN) delivered earnings and revenue surprises of 8.82% and 56.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN)

The heavy selling pressure might have exhausted for Cyclerion Therapeutics, Inc. (CYCN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Ironwood (IRWD) Q3 Earnings Beat on Solid Linzess Sales

Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter.

Ironwood (IRWD) Q2 Earnings Beat on Solid Linzess Sales

Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. COVID-19 impacts enrollment in clinical studies.

Ironwood (IRWD) Misses Q1 Earnings and Revenue Estimates

Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. COVID-19 impacts enrollment in clinical studies.

Ironwood (IRWD) Surpasses Q4 Earnings and Sales Estimates

Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter as well. Stock up.

Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View

Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter as well.

Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates

Ironwood (IRWD) beats on earnings and sales in the second quarter. Demand for Linzess remains strong.

Ironwood Initiates Dosing in Mid-Stage Study for MD-7246

Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.